# Cytarabine in Combination With Arsenic Trioxide vs. Cytarabine Alone in Elderly Patients With Acute Myeloid Leukemia

> **NCT00513305** · PHASE3 · TERMINATED · sponsor: **Cephalon** · enrollment: 67 (actual)

## Conditions studied

- Acute Myeloid Leukemia

## Interventions

- **DRUG:** Arsenic trioxide
- **DRUG:** Low-dose cytarabine alone

## Key facts

- **NCT ID:** NCT00513305
- **Lead sponsor:** Cephalon
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2007-10
- **Primary completion:** 2009-07
- **Final completion:** 2009-12
- **Target enrollment:** 67 (ACTUAL)
- **Why stopped:** Study has been stopped by sponsor decision
- **Last updated:** 2012-08-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00513305

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00513305, "Cytarabine in Combination With Arsenic Trioxide vs. Cytarabine Alone in Elderly Patients With Acute Myeloid Leukemia". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT00513305. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*